<DOC>
	<DOC>NCT02895945</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of BAX 802 in males with congenital hemophilia A (CHA) with inhibitors who are undergoing major or minor elective surgical, dental, or other invasive procedures.</brief_summary>
	<brief_title>BAX 802 in CHA With Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>1. Participant is ≥ 18 to ≤ 65 years old at the time of screening 2. Participant has provided signed informed consent 3. Participant has severe (Factor VIII (FVIII) level &lt; 1%) or moderately severe (FVIII level ≤ 2%) Congenital Hemophilia A (CHA) with inhibitors to human FVIII, as tested at screening at the central laboratory 4. Participant requires elective surgery or other invasive procedures 5. Participant is not currently receiving or has received (&lt; 30 days) immune tolerance induction (ITI) therapy 6. Participant has a Karnofsky performance score of ≥ 60 7. Participant is human immunodeficiency virus negative (HIV); or HIV+ with stable disease and CD4+ count ≥ 200 cells/mm^3 at screening 8. Participant is hepatitis C virus negative (HCV) by antibody or polymerase chain reaction (PCR) testing; or HCV+ with chronic stable hepatitis disease 9. Participant is willing and able to comply with the requirements of the protocol. 1. The participant requires emergency surgery 2. The participant's weight is &lt; 35 kg or &gt; 120 kg 3. Clinically symptomatic liver disease (eg, ≥ 5 X upper limit of normal alanine aminotransferase [ALT], as confirmed by central laboratory at screening, clinical evidence of portal hypertension, severe hypoalbuminemia or a documented prothrombin time/international normalized ratio (PT/INR) &gt; 1.5) 4. Clinically symptomatic renal disease (serum creatinine &gt; 2.0 mg/dL), as confirmed by central laboratory at screening 5. Antiporcine inhibitor &gt; 10 BU prior to surgery 6. Platelet count &lt; 100,000/μL 7. Participant has another active coagulation disorder other than hemophilia A, as per the medical history Planned use of αinterferon with or without ribavarin for HCV infected patients or planned use of a protease inhibitor for HIV infected patients. Patients currently taking any of these medications for ≥ 30 days are eligible 9. Known hypersensitivity to recombinant porcine factor VIII (rpFVIII), or hamster or murine proteins 10. Participant has been exposed to an investigational product (IP) within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study 11. Unable to tolerate quantity of blood to be drawn for protocol procedures 12. Participant is a family member or employee of the investigator.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>